A Pilot project to study the feasibility of interdigitating High Dose Rate brachytherapy with Concurrent Chemoirradiation in Carcinoma Cervix by David, Mathew
1 
 
 
A PILOT PROJECT TO STUDY THE 
FEASIBILITY OF 
INTERDIGITATING HIGH DOSE 
RATE BRACHYTHERAPY WITH 
CONCURRENT 
CHEMOIRRADIATION IN 
CARCINOMA CERVIX. 
 
2 
 
CERTIFICATE 
 
This is to certify that “A pilot project to study the feasibility of interdigitating 
High Dose Rate brachytherapy with Concurrent Chemoirradiation in carcinoma 
cervix” is an original work by Dr David Mathew in partial fulfillment towards 
MD Radiotherapy ( Branch  IX) Degree examination of the Tamil Nadu Dr M 
G R Medical University to be held in March 2010. 
 
 
 
 
  GUIDE                                               --------------------------------------------------- 
Prof.D Subhashini John, DMRT, MD,MNAMS 
       Professor & Head of Department 
                                                     Department of Radiation Oncology 
                                                      Christian Medical College, Vellore 
 
3 
 
ACKNOWLEDGEMENT 
                 I  express my deep gratitude to  Dr Subhashini John for her great patience and 
kindness with which she has guided me in editing and completing this thesis.  She was a constant 
source of inspiration for a high standard in education and continually challenged us to keep upto 
date with the latest developments in the field of Radiation Oncology. I thank Dr B Rajesh for 
guiding me in the write up and in designing the study and who was patient with me where I was 
ignorant.  I am indebted to  Dr Saikat Das for the analysis of the data and for constantly 
demanding excellence from me.  I am  grateful to Dr Patricia for always being there for 
assessment  of  patients  and constantly  encouraging me to do better.  A special thanks to Dr I 
Rajesh  who helped me in getting all the relevant previous studies for the finalization of the 
treatment protocol  and for always  being  a source of  constant motivation to do excellently, 
especially in maintaining a high standard of patient care. 
I would like to express my appreciation to Mr Prassana Samuel for the help in statistical  work 
up  and  Mr  Sathyamoorthy for formatting the data for the same.  I would like to  remember all 
of my friends, colleagues who helped in the translation of the consent  form and who were 
constantly encouraging me whenever I thought to give up.  It  is obvious that without my patients 
cooperation this study would have never progressed beyond the planning stage. 
A  special mention of all my family members who sacrificed their time with me and  always 
prayed and worked with me in completing this work. 
I would like to thank the Almighty Lord who worked through various people and circumstances  
whose continual goodness  never did leave me. 
 
4 
 
TABLE  OF  CONTENTS 
 
 
1 AIM OF THE STUDY------------------------------------------------------------------------------7 
2 INTRODUCTION-----------------------------------------------------------------------------------9 
3 REVIEW OF THE LITERATURE--------------------------------------------------------------11 
3.1 EPIDEMIOLOGY----------------------------------------------------------------------------12 
3.2 RISK FACTORS------------------------------------------------------------------------------12 
3.3 PATHOLOGY---------------------------------------------------------------------------------13 
3.4 CLINICAL PRESENTATION--------------------------------------------------------------17 
3.5 STAGING & WORKUP---------------------------------------------------------------------17 
3.6 TREATMENT WITH RADIOTHERAPY------------------------------------------------21 
3.7 TRIALS WITH RADIOTHERAPY ALONE---------------------------------------------22 
3.8 TRIALS SHOWING BENEFIT OF CONCURRENT CHEMOTHERAPY---------24 
3.9 TRIALS WITH RADIOTHERAPY & CONCURRENT  CHEMOTHERAPY----25 
3.10   TRIALS WITH BRACHYTHERAPY---------------------------------------------------25 
3.11    HIGH DOSE RATE BRACHYTHERAPY FRACTIONATION SCHEDULES‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐27 
       3.11.1  HDR  Brachytherapy after external radiotherapy--------------------------------29 
       3.11.2  HDR Brachytherapy interdigitating with external radiotherapy--------------30 
4 MATERIALS  AND METHODS---------------------------------------------------------------33 
4.1 INCLUSION CRITERIA-------------------------------------------------------------------34 
4.2 EXCLUSION CRITERIA-------------------------------------------------------------------35 
4.3 PATIENT WORKUP AND RECRUITMENT------------------------------------------35 
5 
 
4.4 PRETREATMENT EVALUATION----------------------------------------------------35 
4.5 TREATMENT  SIMULATION---------------------------------------------------------36 
4.6 EXTERNAL BEAM RADIOTHERAPY----------------------------------------------36 
4.7 CONCURRENT CHEMOTHERAPY--------------------------------------------------37 
4.8 INTRACAVITARY BRACHYTHERAPY--------------------------------------------39 
4.9 PRESCRIPTION & DOSE---------------------------------------------------------------40 
4.10   PLANNED TREATMENT SCHEDULE---------------------------------------------41 
4.11   TOXICITY ASSESSMENT-------------------------------------------------------------44 
4.12   BRACHYTHERAPY ASSESSMENT-------------------------------------------------44 
4.13   FIRST FOLLOW UP EVALUATION-------------------------------------------------44 
4.14   STATISTICAL ANALYSIS-------------------------------------------------------------45 
5 RESULTS------------------------------------------------------------------------------------------46 
5.1 PATIENT  TURNOUT----------------------------------------------------------------------48 
5.2 PATIENT  CHARACTERISTICS---------------------------------------------------------49 
5.2.1 Patient characteristics-history-------------------------------------------------------49 
5.2.2 Patient characteristics-examination-------------------------------------------------50 
5.2.3 Patient clinical stage------------------------------------------------------------------52 
5.2.4 Investigation  findings----------------------------------------------------------------52 
5.3 HEMATOLOGICAL TOXICITY----------------------------------------------------------53 
5.4 GASTROINTESTINAL TOXICITY-------------------------------------------------------54 
5.5 NON HEMATOLOGICAL TOXICITY---------------------------------------------------56 
5.6 OTHER TOXICITY--------------------------------------------------------------------------57 
5.7 TREATMENT DELAYS--------------------------------------------------------------------58 
6 
 
5.8 OVERALL TREATMENT TIME---------------------------------------------------------60 
5.9 FAILURE  TO  INTERDIGITATE BRACHYTHERAPY-----------------------------60 
5.10   RESPONSE OF TREATMENT  IN RELATION TO PARAMETERS------------62 
5.10.1 Relation to histological sub type----------------------------------------------------64 
5.10.2 Relation to  technique of radiation--------------------------------------------------65 
5.10.3  Relation to number of chemotherapy ---------------------------------------------66 
6 DISCUSSION--------------------------------------------------------------------------------------67 
7 CONCLUSION & RECOMMENDATIONS--------------------------------------------------75 
8 BIBLIOGRAPHY---------------------------------------------------------------------------------77 
9 APPENDIX ----------------------------------------------------------------------------------------85 
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
 
   AIM   
 
 
 
 
I   AIM OF THE STUDY 
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Primary objectives: 
1. To assess the feasibility of interdigitating High Dose Rate (HDR) brachytherapy with 
External Radiotherapy.  
2. To evaluate the acute toxicity of interdigitating HDR brachytherapy with external 
radiotherapy during the period of treatment.   
3. To study the reasons for not being able to interdigitate brachytherapy with the external 
beam radiotherapy. 
 
Secondary objective:  
1. To assess the possibility of reduction in overall treatment time. 
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II   INTRODUCTION 
Carcinoma of the cervix is one of the commonest malignancies among women in India.  
About 1, 00, 000 women are diagnosed with cervical cancer each year.1 Radiotherapy (both 
teletherapy and brachytherapy) constitutes an integral part in the management of cervical cancer. 
Teletherapy can be delivered by telecobalt or linear accelerator.2,3  Meta - analysis reveals that 
with the addition of concurrent chemotherapy using platinum based drugs the overall absolute 
survival is increased by 12%.4  Various studies indicate that the success of treatment depends on 
the completion of full treatment within 8 weeks. Several studies have shown that there is a 
decrease of overall survival by 1% per day beyond 8 weeks.5 In view of this it is imperative to 
complete the full treatment including brachytherapy within 8 weeks. Since with HDR 
brachytherapy multiple applications are required, if done after completion of EBRT this would 
result in prolongation of treatment time beyond 8 weeks. Therefore many groups have tried to 
interdigitate brachytherapy with external radiotherapy. 
The primary concern of HDR Brachytherapy is the potential late toxicity of large dose per 
fraction, which can be overcome through adequate fractionation.3 Additionally in HDR, late 
tissue complications might be minimized more effectively than in LDR, because greater normal 
tissue displacement (e.g., bladder anteriorly and rectum posteriorly) is possible because of the 
short treatment times and available retraction devices. The risk of bladder and rectal 
complications depends upon the doses received by the bladder and the rectum.  
The aim of this study is to assess the feasibility and tolerability of interdigitating HDR 
brachytherapy with External radiotherapy in carcinoma cervix in our patients.  
11 
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III  REVIEW OF LITERATURE   
3.1Epidemiology 
Carcinoma of the  cervix is the 6th most common malignant neoplasm in  human after carcinoma 
breast, lung, colorectal, endometrial and ovary. Carcinoma of the cervix is the second leading 
cause of female cancer deaths in the underdeveloped countries.6  Carcinoma cervix is more 
common in women who had first intercourse at an early age, have a history of  promiscuity and 
large number of pregnancies.7, 8, 9 
The most common type of invasive cancer of the cervix is squamous cell carcinoma,  with  
subtypes, papillary (squamotransitional) subtype, the verrrucous subtype and the 
lymphoepithelioma-like subtype10 
 3.2 Risk Factors 
A retrospective analysis though surrounded by many controversies undertaken by Kapp et al, in 
an attempt to identify prognostically significant pretreatment factors showed that FIGO stage is 
an important prognostic factor along with other factors including patient age at diagnosis, 
pretreatment neutrophil count and hematocrit, uterine position, prior subtotal hysterectomy, 
histology, history of diabetes mellitus and number of pregnancies.  When all other factors 
including stage was controlled for, increased tumor size was associated with decrease disease-
free survival and local-regional control rates.11 
Some of the studies which have reported prognostic factors and is suggested to be included in the 
staging system are depth of stromal invasion, tumor size, presence or absence of lymphatic 
vascular space invasion, pelvic lymph node status, tumor volume, endometrial extension of 
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cervical carcinoma, and parametrial involvement.12 Other patient factors which have been 
extensively studied are the age13 and the socioeconomic factor.14 Medical factors include 
Anemia,15 Tumor hypoxia. Others under consideration are arterial hypertension, fever, HIV.16 
When we consider lymphatic spread and the various types of histology, positive lymph nodes are 
found in adenocarcinomas much higher than in squamous cell carcinoma, showing the difference 
in their behavior. It was also found by Korhonen et al that there is no significant difference in 
survival rate between pure adenocarcinoma, adenosquamous carcinoma, clear cell 
adenocarcinoma and adenocarcinoma.  It was also found that the histological grade had a direct 
correlation to the survival rate; for grade I tumors it was about 60%, whereas for patients with 
grade IV tumors only about 10% survived. 17 
3.3 Pathology  
Although squamous cell carcinoma is the most common type of carcinoma of cervix other 
histological types can also be seen.  Given below is WHO classification of the various 
histological types. 
Carcinoma of cervix--(WHO classification of cervical tumors)18 
Epithelial tumors 
Squamous lesions and precursors     
Squamous cell carcinoma, not otherwise specified 
1. Keratinizing 
2. Nonkeratinizing 
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3. Basaloid 
4. Verrucous 
5. Warty (condylomatous) 
6. Papillary (transitional) 
7. Lymphoepithelioma-like 
8. Squamotransitional 
9. Early invasive (microinvasive) squamous cell carcinoma 
10. Squamous intraepithelial neoplasia / lesions (SIL) 
11. High grade (usually lumped with carcinoma in situ) or low grade 
12. Cervical intraepithelial neoplasia (CIN) - different terminology than SIL 
13. CIN 1 (mild dysplasia, low grade SIL) 
14. CIN 2 (moderate dysplasia, high grade SIL) 
15. CIN 3 (severe dysplasia, carcinoma in situ, high grade SIL) 
16. Benign squamous cell lesions 
17. Condyloma acuminatum 
18. Squamous papilloma 
19. Fibroepithelial polyp 
Glandular tumors and precursors 
1. Adenocarcinoma 
2. Mucinous adenocarcinoma (endocervical, intestinal, signet ring, minimal deviation, 
villoglandular subtypes) 
3. Endometrioid adenocarcinoma (may have squamous metaplasia) 
4. Clear cell adenocarcinoma 
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5. Serous adenocarcinoma 
6. Mesonephric adenocarcinoma 
7. Early invasive adenocarcinoma 
8. Adenocarcinoma in situ 
9. Glandular dysplasia 
10. Benign glandular lesions 
11. Mullerian papilloma 
12. Endocervical polyp 
13. Other epithelial tumors 
14. Adenosquamous carcinoma 
15. Glassy cell carcinoma variant 
16. Adenoid cystic carcinoma 
17. Adenoid basal carcinoma 
18. Neuroendocrine tumors 
19. Carcinoid tumor 
20. Atypical carcinoid tumor 
21. High grade neuroendocrine carcinoma - small cell or large cell types 
22. Undifferentiated carcinoma 
Mesenchymal tumors and tumor like conditions 
1. Leiomyosarcoma 
2. Endometrioid stromal sarcoma, low grade 
3. Undifferentiated endocervical sarcoma 
4. Embryonal rhabdomyosarcoma (sarcoma botyroides) 
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5. Alveolar soft parts sarcoma 
6. Angiosarcoma 
7. Malignant peripheral nerve sheath tumor 
8. Leiomyoma 
9. Genital rhabdomyoma 
10. Postoperative spindle cell nodule 
Mixed epithelial and mesenchymal tumors 
1. Carcinosarcoma (malignant mullerian mixed tumor) 
2. Adenosarcoma 
3. Wilms tumor 
4. Adenofibroma 
5. Adenomyoma 
6. Melanocytic tumors 
7. Malignant melanoma 
8. Blue nevus 
Miscellaneous tumors 
     Germ cell tumors (yolk sac tumor, dermoid cyst, mature cystic teratoma) 
Lymphoid and hematopoietic 
     Malignant lymphoma (specify type) 
     Leukemia (specify type) 
Secondary tumors 
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3.4 Clinical Presentation 
Early invasive carcinoma of the cervix can be detected before it becomes symptomatic by 
cytological smears. Serosanguineous or yellowish, foul-smelling vaginal discharge may be noted 
in patients with invasive carcinoma, particularly with more advanced necrotic lesions. If chronic 
bleeding occurs, the patient may complain of fatigue or other symptoms related to anemia. 
Pain, usually in the pelvis or hypogastrium, may be noted and could be caused by tumor necrosis 
or associated pelvic inflammatory disease. Some patients may complain of pain in the 
lumbosacral area, and in these cases the possibility of paraaortic lymph node involvement with 
extension in to the lumbosacral roots or hydronephrossis should be considered. Occasionally 
epigastric pain may be caused by metastasis to high para-aortic lymph nodes. 
Urinary and rectal symptoms (hematuria, rectal bleeding) may appear in advanced stages as a 
consequence of invasion of the bladder or rectum by the neoplasm. 19 
3.5 Staging and workup 
It is recommended that all patients with carcinoma cervix should be jointly evaluated by the 
radiation and gynecologic oncologist. Detailed history and physical examination of the patient 
including a pelvic examination should be done. Special attention to the supra clavicular nodal 
areas abdomen and liver should be carried out. Pelvic examination should include inspection of 
external genitalia, vagina and uterine cervix, rectal examination and bimanual palpation of the 
pelvis. Cystoscopy or rectosigmoidoscopy should be performed in all patients with stage IIB and 
more advanced disease and in those patients who gives a history of urinary or lower 
gastrointestinal tract complaints.20 
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Staging of Carcinoma of the uterine cervix is staged and managed by means of the International 
Federation of Gynecology and Obstetrics (FIGO) staging system. The FIGO staging system is 
determined preoperatively mainly by the clinical assessment. This was seen to be quit sufficient 
for early stage disease, but it has inherent inaccuracies in advanced stage disease. It does not take 
into account the nodal involvement. Though not routinely used in the developing countries, CT 
and MR imaging are widely used elsewhere to evaluate tumor size and extent, and nodal 
involvement. In this it was found that MR imaging is excellent for depicting invasive cervical 
carcinoma with objective measurement of tumor volume. It rules out conclusively parametrial 
invasion and stage IVA disease.21 
Cervical cancer staging is the oldest staging in the literature, dating back to 1928. Classification 
of the Stages of Carcinoma of the Uterine Cervix is done by International Federation of 
Gynecology and Obstetrics. Since the initial staging was introduced by them, the staging for 
cervical cancer has undergone 7 revisions, last was in 1994.  The controversies surrounding 
cervical cancer staging has contributed to yet another revision in 2009 and published in 
International journal of gynecology and obstetrics which is the official organ of the FIGO.22 
 
 
 
 
 
The following is the recommended investigations for the work up of carcinoma of cervix; 
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Diagnostic work‐up for carcinoma of the uterine cervix23 
General  *History
*Physical examination, including bimanual pelvic 
and rectal examinations 
Diagnostic 
procedures 
*Cytological smears(Papanicolaou) if not bleeding
*Colposcopy 
*Conization (subclinical tumor) 
*Punch biopsies (edge of gross tumor, four  
quadrants) 
*Dilatation and curettage 
*Cystoscopy, rectosigmoidoscopy(stages IIB, III, 
and IVA 
Radiographic Studies  Standard
  *Chest radiography 
  *Intravenous pyelography 
  *Barium enema (stages III and IVA and earlier          
stages if there are symptoms referable to colon or 
rectum)  
Complementary 
   *Lymphangiography 
   *Computed tomography or magnetic resonance 
imaging  
   *Positron emission tomography scan(optional) 
Laboratory studies     *Complete blood count
   *Blood chemistry  
   *Urinalysis 
 
 
Cytology 
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The American cancer society has recommended that asymptomatic women 20 years of age and 
older, and those younger than 20 yrs who are sexually active have a papanicolaou smear annually 
for 2 consecutive yrs and at least 1 every 3 yrs until the age of 65.24 Women who have high risk 
for development of cervical carcinoma should have a yearly smear. If the cytological smear 
shows dysplasia and malignant cells colposcopy directed biopsies should be carried out 
immediately. 
Colposcopy 
Colposcopy is useful in detecting majority of the early cervical lesions if it is combined with 
cytology examination and biopsy of grossly abnormal size. 
Conisation 
It is performed in specific situations when an endocervical tumor is suspected, when the entire 
lesion cannot be seen by colposcope, when the diagnosis of microinvasive carcinomas made on 
biopsy or the patient is not reliable for continuous follow up. 25It involves conical removal of 
large portion of exocervix and endocervix. At least 50 percent of endocervical canal should be 
removed without compromising the internal sphincter. Curettage of the remaining endocervical 
canal should be carried out. 
Biopsy 
When a gross lesion of the cervix is present multiple punch biopsies are done from the suspect 
area, all four quadrants of the cervix and suspect area in the vagina. It is important to obtain 
tissue from the periphery of the lesion with some adjoining normal tissues. 
Dilatation and Curettage 
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Fractional curettage of endocervical canal and endometrial is recommended to plan therapy for 
the possible extension of upper extension of tumor when indicated. 26 
Laboratory studies 
Blood tests included serum for Biochemistry – creatinine and liver function tests, blood for 
Pathology-hemoglobin, total count with differentials, platelets, and Virology sample for Blood 
Borne Viruses, and  urine analysis. 
Radiological tests- Chest X-ray (PA), and intravenous pyelogram is recommended for all  
patients.  A colon barium enema is advised  for all patients with stage IIB and more advanced 
disease and in those patients who gives a history of urinary or lower gastrointestinal tract 
complaints.27 Those who afford can do USG abdomen and pelvis (or CT) instead of the same.  
Management for locally advanced (Stage 2b and 3b) 
3.6 Treatment  with radiotherapy  
Radiotherapy is the mainstay of treatment in carcinoma of cervix. Radiotherapy is delivered  by a 
combination of external beam photon therapy and brachytherapy. External irradiation is used to 
treat the whole pelvis and parametrium including the common iliac  nodes whereas the central 
disease- cervix, vagina and the medial pat of the parametrium is primarily irradiated with the 
intracavitary  sources. 
External beam irradiation- It is delivered before intracavitary insertions in patients with a) bulky 
cervical lesions or tumors beyond stage IIA to improve the geometry of the intracavitary 
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application; b) exophytic easily bleeding tumors, c) tumors with necrosis or infection, d) 
parametrial involvement.28 
Tumor Volume 
It is important to deliver the adequate doses of irradiation not only to the primary tumor and to 
the pelvic lymph nodes. The common iliac bifurcation being cephalad to the lumbosacral 
prominence, the superior border of the pelvic portal should be at the L4/L5 inter space to include 
all of the external iliac and the hypogastric lymph nodes. This margin is extended to the L3/L4 
interspace if common iliac nodes are to be covered. A 2 cm margin lateral to the bony pelvis is 
adequate. If there is no vaginal extension, the lower border of the portal is at the inferior border 
of the obturator foramen. If the vagina is involved, the entire length upto the introitus  should be 
treated. In patients with tumor involving the distal half of the vagina, the portal fields should 
include the inguinal lymph nodes. The anterior border of the lateral field is  kept 3 cm in front of 
the anterior surface of  the L4 vertebral body or at the pubic symphisis and posteriorly at the 
S2/S3 junction. In locally advanced tumors the posterior border maybe extended to include the 
entire sacral hollow.29 
3.7 Trials with radiotherapy alone 
Denton et al did a study to investigate the UK prevalence of late, severe side-effects associated 
with radical radiotherapy for cancer of the cervix and associated factors. 53 departments in UK 
out of 55 participated in the study. There were 1558 patients with carcinoma of the cervix 
receiving radical radiotherapy. Late severe complications in the year 1993 was 6.1% (actuarial 
rate 8%) at 5 years. Only 4 out of the 91 patients who developed complications died as a result of 
their morbidity. There was no significant correlation of stage, centre size, surgery or radio 
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therapeutic approach with late morbidity. The only factor significantly associated with mortality 
was the FIGO staging.30 
Yalman et al did a study to evaluate early and late radiation morbidity in patients with cervical or 
endometrial cancer treated by a combination of external radiotherapy (ERT) and intracavitary 
brachytherapy (IBRT). Early and late radiation morbidity were evaluated retrospectively using 
RTOG/EORTC criteria. Total doses at the vagina, bladder and rectum in operated cervix cancer 
patients were 60.51 Gy, 56.53 Gy and 55.67 Gy, respectively. BED for the same points were 
79.77, 69.36 and 67.52, respectively for early effects and 124.74, 99.3 and 95.17, respectively for 
late effects. 38.1% developed early morbidity. Grade I and II bladder morbidity was the most 
common type.  30.9% developed late morbidity, vaginal morbidity being the most common type. 
Total doses at the vagina, bladder and rectum in inoperable patients were 70.92 Gy, 66.71 Gy 
and 62.38 Gy, respectively. BED for the same points were 97.43, 89.64 and 81.63, respectively 
for early effects and 159.3, 143.16 and 126.56, respectively for late effects. 39% developed acute 
morbidity which was grade I or II bladder morbidity in 95%. 61.7% developed late morbidity 
which was grade I-III vaginal morbidity in 94%. It concluded that patients with cervical or 
endometrial cancer can be treated safely by a combination of ERT and IBRT. However the 
patients should be assessed before, during and after treatment and at every period of follow-up to 
monitor the morbidity rate.31 
Potter et al tried to compare small tumors against large tumors. The mean dose for brachytherapy 
was 16.2 Gy at the ICRU rectum reference point and 14.4 Gy at the ICRU bladder point. Taking 
into account the dose for EBT, the mean isoeffective dose at the ICRU rectum reference point 
was 69.9 Gy. Overall treatment time was six weeks for small tumors and eight weeks for large 
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tumors.  The actuarial late complication rate for grades 3 and 4 was 2.9% for the bladder, 4.0% 
for the bowel, 6.1% for the rectum and 30.6% for the vagina. Overall toxicity was comparable to 
other reports. He recommended increasing the therapeutic window by integrating MRI into 
treatment planning, allowing for a highly individualized approach.32 
3.8 Trials showing benefit of  concurrent chemotherapy 
NCI alert was issued in February 1999 based on the publication of five randomized trials which 
suggested that platinum based concurrent chemoirradiation should be the first line treatment for 
carcinoma cervix. They again confirmed the addition of cisplatin showed the superiority of 
chemo irradiation  with an absolute survival benefits of 12 % at the end of 5 years.  This has 
become the basis of widespread practice.33 
Morris et al in his study confirmed the superiority of chemoirradiation over radiotherapy alone 
after comparing the 5 year overall and disease free survival.34 
A Canadian meta-analysis based on 8 randomized studies that evaluated the role of concurrent 
cisplatin demonstrated a statistical significance in favor of cisplatin with a reduction in the 
overall relative risk ranging from 30 to 50 % across  all stages.35 
The meta-analysis done by Green et al based on the Cochrane data of 19 trials , 12 based on 
cisplatin chemotherapy, estimated an absolute improvement in overall survival rate of 12 % from 
40 % to 52 % with a 29% reduction in the risk of death. There was an absolute improvement in 
the progression free survival of 13 % from 47 % to 63 %. There was  clear decrease in the local 
recurrence rate and the distant recurrence rate with chemoirradiation.36 
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3.9 Trials with radiotherapy and concurrent chemotherapy 
It has been proved by Sood et al that, concomitant chemotherapy with pelvic irradiation has 
improved survival among patients with locally advanced carcinoma of the cervix.  Each patient 
underwent two applications of high-dose-rate brachytherapy, 1 week apart. An important issue 
was the toxicity of concomitant chemotherapy. A retrospective analysis of radiotherapy and 
high-dose-rate brachytherapy with or without concomitant chemotherapy showed that most 
patients (93%) who received chemotherapy suffered from acute toxicity, including hematologic 
toxicity, gastrointestinal toxicity, and deep venous thrombosis. The actuarial incidence of late 
toxicity was 6%.37 
Souhami et al did a study to assess the toxicity of the concomitant use of weekly cisplatin and 
pelvic radiotherapy in patients with locally advanced carcinoma of the cervix with Cisplatin 30 
mg/m2. It was found to be well tolerated. No patient required an interruption in the radiotherapy. 
However, late gastrointestinal toxicity appeared sooner than expected, at a median follow-up 
time of 11 months after completion of treatment. 38 
3.10 Trials   with   brachytherapy 
When High-dose-rate brachytherapy was introduced in the treatment of cervical cancers, one of 
the concerns was about the toxicity. A retrospective analysis done by Macleod et al reported a 
severe late toxicity rate of 4.9%. These results were similar to other reported international studies 
that have used either low-dose-rate or high-dose- rate brachytherapy.39 
Various other more aggressive treatment schedules have been practiced elsewhere with HDR 
brachytherapy. Yoon et al gave a daily fraction dose of 1.8 Gy administered in six-weekly 
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fractions, from Monday to Saturday. HDR brachytherapy was also delivered in six fractions 
twice a week. Grade 2 and 3 late rectal complications were encountered in 6.5% and 2.2%, 
respectively. There were no Grade 3 late bladder complications. They concluded that Six 
fractions per week of external beam radiotherapy and HDR brachytherapy is effective treatment 
which therefore can be used for patients with carcinoma of the uterine cervix who cannot be 
treated with concomitant chemo radiotherapy, like the elderly, or those with multiple medical co-
morbidity.40 
Takeshi et al also found comparable toxicity. External beam radiotherapy and intracavitary 
brachytherapy  using a high-dose-rate 60Co source was used. The 5-year incidence was 2.6% for 
major bladder complication and 8.3% for major rectal complication. They observed that the 
higher radiation dose was given in those patients having rectal complication. He also 
recommended that high-risk patients should be treated with concurrent, chemotherapy.41 
Other types of application also has shown similar results. A single line  source brachytherapy 
technique was used at Clatterbridge to boost the dose to the primary tumor after external beam 
radiotherapy (EBRT) for the radical treatment of carcinoma of the cervix.  Radiotherapy  
alone was used. The actuarial rate of Grade 2 late radiation morbidity was 2.7% and 4.3% for the 
urinary tract and bowel respectively while that of Grade 3 morbidity was only 0.6% and 1.4%, 
respectively.42 
Studies by Khoo Tan et al using initially external beam therapy followed by high dose rate 
brachytherapy also got low complication rate. It reported a serious complication rate of 1.7% 
only.43 
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3.11 High dose rate brachytherapy fractionation schedules 
There were multiple trials in which HDR brachytherapy was fractionated, some interdigitated 
with the external radiotherapy. They have followed various protocols and the following studies  
were considered before finalizing our protocol.  
Author & Reference 
Numb
er 
Concurrent 
Chemother
apy 
Fractionation 
Toxicity 
(%) 
Outcome 
Overall 
treament 
time(days). 
Yukihiro Hama, 
et..al..Radiology. 
2001;219:207‐212. 
74 
Nil  7Gy x 3# once 
weekly  32 
os‐65 dfs‐
69  (51) 
50 
Nil  4.5Gy x 6# twice 
weekly  6 
os‐65 dfs‐
90  (48) 
Huh SJ et..al.. J Korean Soc 
Ther Radiol Oncol. 2002 
Sep;20(3):237‐245. Korean.  106 
Nil 
24 to 28Gy in 6 or 7 
# twice weekly  13 
os‐73dfs‐
69 pcr‐79 
44 to 104 
(55) 
Shang‐Wen Chen 
et..al..Radiotherapy and 
Oncology 67 (2003) 69–76 
257 
Nil (45 
adjuv)  7.2Gy x 3# once 
weekly 
rect‐25 
bow‐6 
bld‐3  * 
47 to 92 
(63) 
257 
Nil 
6Gy x 4# once 
weekly 
rect‐25 
bow‐6 
bld‐3  * 
47 to 92 
(63) 
Robson Ferrigno et..al..Int. J. 
Radiation Onco Biol. Phys., 
Vol. 50, No. 5, pp. 1123–
1135, 2001  138 
Nil 
6Gy x 4# once 
weekly 
rect‐16 
bow‐14 
bld‐11 
os‐57 dfs‐
52  pcr‐62 
39 to 
193(60) 
Prasert Lertsanguansinchai 
et..al..Int. J. Radiation Onco 
Biol. Phys., Vol. 59, No. 5, 
pp. 1424–1431, 2004 
112 
Nil 
7.5Gy x 3# once 
weekly 
rect‐19 
bow‐3 
bld‐15 
os‐69 dfs‐
70  pcr‐87  <49 
112 
Nil 
8.3Gy x 2# once 
weekly 
rect‐19 
bow‐3 
bld‐15 
os‐69 dfs‐
70  pcr‐87  <49 
Firuza D Patel et..al..Int. J. 
Radiation Onco Biol. Phys., 
Vol. 62, No. 1, pp. 125–130, 
2005 
113(1
8) 
Nil 
9Gy x 5# once 
weekly  3 
os‐62  pcr‐
74  <42 
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Os less than 63 days more or equal to 63 days 
Ib/IIa 97 79 
IIb 75 72 
III 66 49 
Pcr     
Ib/IIa 100 87 
IIb 93 87 
III 83 72 
 
   
 
 
 
 
 
 
3.11.1 Trials with HDR brachytherapy after external radiation 
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Yukiro Hama et al recommended that The twice-weekly HDR regimen may improve the local 
control rate with fewer complications  than once weekly regime. He conducted a study with two 
different fractionation schedules of HDR brachytherapy after external radiotherapy in which  74 
patients were treated with weekly once fractionation of  7Gy for 3 applications. The overall 
treatment time was reduced to 51 days and acute toxicity was reported as 32 percent. He also 
treated 50 patients  with 4.5Gy weekly twice fractionation for 6 applications. The overall 
treatment time was reduced to 48 days and acute toxicity was only 6 percent.44 
Huh SJ et al concluded that 24-28Gy in 6 0r 7 applications with twice weekly fractionation is a 
safe and effective treatment for patients with uterine cervix cancer.  He also found out that OTT 
of less than 55 days had a positive impact on pelvic control and survival rate. 
He conducted a study on 106 patients who had radiotherapy with radical intent. The median age 
was 61 years. He gave  30.6 to 50.4 Gy external beam radiotherapy to whole pelvis with 
brachytherapy dose of 24~28 Gy in 6~7 fractions to point A at two fractions per week. The 
median range of overall treatment time was 55 days and toxicity was 13 percent rectal bleeding, 
which occurred around 13 months after the completion of radiotherapy. The overall survival rate 
was found to be  82%, and 73%, and the disease free survival rate was 72%, and 69%,  with  a  
pelvic control rate of 79% at 3, and 5 years, respectively. 
Shang-wen Chen et al recommended to consider changing brachytherapy strategy such that the 
treatment duration is shortened.   He found that the risk of major late complications was not 
significantly associated with treatment duration. He did a two arm study on 257 patients in which 
HDR brachytherapy was administered after the completion of external radiotherapy. 93 patients 
had dose modification to point A to 5 Gy who were treated with an initial calculated  rectal dose 
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of over  6.0 Gy One arm received 7.2Gy weekly once fractionation for 3 applications and the 
other arm was 6Gy weekly once fractionation for four applications. He reported median overall 
treatment time of 63 days with the acute toxicity in rectum 25%, bladder 3%, bowel 6%.45 
 
3.11.2 Trials with HDR brachytherapy interdigitating with external radiotherapy. 
 
 Robson et al suggested that 45 Gy to the whole pelvis combined with four fractions of 6 Gy to 
point A with HDR brachytherapy is an effective and safe fractionation schedule in the treatment 
of Stages II and III cervix cancer if realized up to 50 days.  He did a study on 138 patients. They 
were treated with a dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Parametrial boost 
was performed in 128 patients (93%) with gross parametrial invasion by placement of a 4-cm 
rectangular midline shielding of 5 Half Value Layers at anterior and posterior 
fields. All patients were evaluated after the second week of pelvic external radiotherapy for 
intracavitary brachytherapy. Whenever possible, HDR was performed during the external 
radiotherapy course. In cases of unsuitable conditions for intracavitary insertion, HDR 
brachytherapy was performed after completion of external radiotherapy. He gave 6Gy weekly 
once fractionation for 4 applications and had median overall treatment time of 60 days with the 
acute toxicity in rectum 16%, bladder 11%, bowel 14%.46 
Prasert et al found that there was comparable outcomes between  between LDR and HDR 
intracavitary brachytherapy. He recommended that due to patient convenience, the lower number 
of medical personel needed, and decreased radiation to health care workers, HDR intracavitary 
brachytherapy is an good alternative to conventional LDR brachytherapy. In his study  
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 multiple fractions of brachytherapy were integrated with external radiotherapy. Thus the entire 
treatment was completed within 7 weeks. The external radiothererapy dose per fraction was 2 Gy 
in all patients. After a dose of 40–50 Gy to the whole pelvis, the patients were evaluated for 
intracavitary brachytherapy insertion. Brachytherapy insertions were performed weekly and 
combined with external radiotherapy (with central shielding) by giving four fractions of 
teletherapy weekly with one brachyhtherapy per week. The dose schedules and fraction of 
brachytherapy depended on the dose at point A already delivered  before central shielding. The 
shielding of the central structures are done as they receive high doses from brachytherapy.After 
central shielding, additional external radiotherapy to the pelvic lymph node and parametrium was 
given to 50–54 Gy. His  study was done on 112 patients. One group received 7.5Gy weekly once 
fractionation for 3 applications and the other group received 8.3Gy weekly once fractionation for 
2 applications. The overall treatment time was restricted within 49 days and the acute toxicity in 
rectum 19%, bladder 15%, bowel 3%.47 
Firuza D patel et al proved that HDR brachytherapy at 9 Gy/fraction is both safe and effective in 
the management of carcinoma of the cervix, with good local control and a minimum of normal 
tissue toxicity . These patients underwent simultaneous external radiotherapy and HDR 
brachytherapy. External radiotherapy was given to the pelvis with central shielding throughout 
treatment to a dose of 40 Gy in 20 fractions within 4–5 weeks. Intracavitary brachytherapy 
was interdigitated with external radiation. Weekly sessions of 9 Gy of HDR brachytherapy were 
given from the start of treatment for a total of five sessions. Patients did not undergo external 
radiation on the day of  brachytherapy. She had two groups of patients, Group 1 patients had  a 
4-cm-wide central block  used throughout the externa radiation to shield the central structures 
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The  Group 2 had Stage IIb–IIIb disease with a tumor size _4 cm and distorted cervical anatomy. 
They underwent external radiotherapy to the whole pelvis to a dose of 46 Gy in 23 fractions 
within 4.5–5 weeks followed by two appliacations of intracavitary brachytherapy 
of 9 Gy each, given 1 week apart. Whole pelvis irradiation was delivered with a dose of 200 
cGy/fraction five fractions weekly. 
Modification of the treatment plan was required for 4 patients with a rectal dose of _80% of the 
dose to point A The overall treatment time was less than 42 days and acute toxicity of 3% was 
reported. So she proved that high dose rate of 9 Gy is well tolerated in Indians.48 
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           MATERIALS  AND METHODS 
 
 
 
 
 
IV    MATERIALS AND METHODS 
Methodology  
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All patients who have come to the Department of Radiotherapy with biopsy proven carcinoma 
cervix were considered for the participation in the trial. They were enrolled after signing the 
informed consent. 
4.1 Inclusion Criteria  
The patients were screened for the following inclusion criteria and then enrolled.   
1. Carcinoma cervix stage IIA to IIIB with Histological confirmation  (squamous cell, 
adenocarcinoma, and adenosquamous carcinoma) 
2. ECOG Performance Status score 0-2 
3. Adequate bone marrow function: White Blood Cells > 3000/mm3 (ANC ≥ 1800/mm3); 
platelets > 100,000 mm3; 
4. Adequate renal function: Creatinine < 1.5 mg/dl (urinary diversion is permitted to 
improve renal function); patients must have Bilirubin < 1.5 mg/dl, ALT / AST ≤ 2 x 
normal Alkaline phosphatase. Should give an informed consent prior to participation in 
study.  
5. People of child bearing potential should be willing to practice contraception. 
6. Patients responding to radiation therapy and subsequently treated with brachytherapy, 
were included for analysis. 
 
 
4.2 Exclusion Criteria  
1. Previous history of  tumor-directed surgery 
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2. Previous  history of systemic chemotherapy  
3. Previous history of pelvic radiation therapy 
4. Pregnancy  
5. Presence of Metastatic disease 
6. Severe co morbid medical condition 
Patients who did not respond to radiation therapy and therefore subsequently could not be treated 
with brachytherapy were not considered for analysis. 
4.3 Patient workup scheme and recruitment: 
The patients who fulfilled the inclusion and the exclusion criteria were selected for the study.  
The history and clinical examination findings were reviewed and the lab investigations were 
followed up.  All suitable subjects were explained about the study, and were provided with the 
literature regarding the study. After reading it and the clarification of any doubts, they were 
enrolled into the study after obtaining their written informed consent before starting the 
treatment. 
4.4 Pre Treatment evaluation: 
After obtaining a detailed history all patients are subjected to a thorough clinical examination.  A 
cervical biopsy was done  to confirm the diagnosis.   
 Blood tests-- Biochemistry-- Renal Function Tests / Liver Function Tests  
--Pathology--Complete Blood Counts 
-- Virology --Blood Borne  Viruses.  
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Urine analysis--Microscopy / Culture / Pregnancy tests where indicated 
Cystoscopy and Proctoscopy. 
Radiological tests--Chest X-ray (PA), Ultrasonogram abdomen and pelvis (or CT scan).  
Baseline ECG. 
4.5 Treatment simulation 
All patients underwent treatment simulation, prior to initiation of radiotherapy. The treatment 
portals were marked over the patient and if necessary, the field centers were tattooed. Check 
films were taken for record.  A cross sectional contour of the patient at the treatment centre was 
taken and tumor volume was drawn. Then it is transferred onto the treatment planning system for 
finalizing the beams, wedges and the doses.  
4.6 External Beam Radiotherapy 
Radiotherapy was delivered using Co 60- Theratron 780C machine or the Linear Accelerator. 
The Anterior pelvic field extended from L4/L5 space to the lowest level of the disease with 2 cm 
margins and laterally 1.5 to 2 cm beyond the lateral margin of the bony pelvic wall. The anterior 
border of the lateral fields was kept 3 cm in front of the anterior surface of the L4 vertebral body 
and posterior at the S2/S3 junction or the sacral hollow was included if required. The upper and 
lower borders were same as the upper and the lower border of the anterior field. Modification 
was made for inclusion of nodes or gross tumor as necessary.  Total dose of 50 – 50.4 Gy to 
target volume was given by four field box technique in 25-28 fractions for 5 days in a week 
(except on those days when brachytherapy was applied) over a period of 5 to 51/2 weeks.  
4.7 Concurrent chemotherapy 
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All patients were planned for concurrent chemo radiotherapy with Cisplatin 40 mg per square 
meter weekly infusion after checking that the blood tests were within normal limits and after 
ruling out infection. Cisplatin was given with short hydration and Inj. Dexamethasone 4mg and 
Inj. Ranitidine 50 mg along with Inj. Ondansetron 8mg as premedication.  Following 
chemotherapy they received Dexamethasone, Ranitidine and Odansetron orally for the next 3 
days.   
The first cycle of Chemotherapy was given on the day of initiation of radiotherapy.  It was given 
once a week during radiotherapy with a gap of 7 days from the previous date of chemotherapy.  
The chemotherapy was administered 1 hour prior to radiotherapy in the day care centre.  
Chemotherapy was continued if there was normal blood counts and creatinine along with normal 
creatinine clearance.  If the creatinine clearance was below 40 then chemotherapy was omitted.   
If the creatinine clearance was between 40 – 50, 50 % of the calculated dose  was given,  if 50 - 
60 then 75 % of the calculated dose was given and full dose if clearance was above 60. The 
modified dose of Cisplatin was given as per  recommendation of the Avon, Somerset and 
Wiltshire Cancer Services(ASWCS) cisplatin protocol.  Total WBC should be > 4000/mm3 
(ANC ≥ 1800/mm3); platelets > 100,000 mm3;patients must have, ALT / AST ≤ 2 x normal 
range, normal Alkaline phosphatase. One patient had received 45 mg weekly, 2 patients 50 mg 
and  while 4 of them received 55 mg and 6 of them had 60 mg weekly cisplatin. One patient had 
to receive dose modification due to persistent low creatinine clearance. 
The following chemotherapy schedule with short hydration was followed in the administration of 
the concurrent chemotherapy. 
                            RADIOTHERAPY DEPARTMENT  
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   CHRISTIAN MEDICAL COLLEGE AND HOSPITAL, VELLORE.  
                    CHEMOTHERAPY INSTRUCTION SHEET 
Name:                                                        H. No.   
   
HEIGHT                         WEIGHT      BSA   
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
Name of drug                 Dose               Route                   Days  
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
Inj. Cisplatin*      (40 mg/m2) IV in 1 pint normal saline    weekly 
                      over 1 hour with hydration* and premedication**      
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
    1.  Repeat the course after _7__ days from Day _1__  
   2.  The following investigations must be done before chemo.  
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
  Investigation(s)      }            
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
  Hb, Platelet, WBC}    before each course                       
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
   S.Creat                   }   before each course    
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐  
   LFT                        }   before each course  
‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ 
  
    4.  If the serum creat or  LFT is abnormal, if the WBC falls      below 4000/cumm platelet 
below 100,000/cumm and Hb below 8gm and if toxic symptoms like severe vomiting, diarrhoea, fall of 
BP and mucositis of buccal mucosa develop, the drugs are to be discontinued.  After a period of 4 to 5 
days if the counts regain normal values, the drugs may be continued as instructed after careful re‐
evaluation of the patient's condition.  
   
*HYDRATION SCHEDULE TO BE FOLLOWED FOR INJ. CISPLATIN:  
 
Inj. Dextrose Normal saline 1000 ml over 2 hours  
Inj. Mannitol 12.5% 100ml over 1/2 hour   
 
Premedication 
 
Inj. Cisplatin in 300 ml Normal saline over 1 hour  
 
Inj. Dextrose Normal saline 500 ml  over 1 hour   
  
 
**ANTIEMETIC REGIME FOR CISPLATIN BASED CHEMOTHERAPY.  
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1.Inj. Dexamethasone 8 mg IV stat before cisplatin    
2.Inj. Ondansetron 8 mg IV stat before cisplatin.  
3.Inj. Ranitidine 50 mg IV stat  before cisplatin  
4.Inj. Ondansetron 8 mg IV after 6 hours after cisplatin 
 
Post chemotherapy antiemetic regimen:  
 
1. Tab. Dexamethasone 4 mg twice daily X 3 days 
2. Tab. Ranitidine 150 mg twice daily X 3 days.   
3. Tab. Lorazepam 1 ‐ 3 mg at bed time.  
4. Tab. Emeset 8 mg as necessary for nausea. 
 
 
4.8 Intracavitary brachytherapy 
The patient was admitted in the ward one day prior to the  procedure.  All patients had soap  
water enema for bowel preparation and vaginal douche prior to the intracavitary applicator 
placement. The patient was on soft diet. 
PROCEDURE 
After positioning the patient in the lithotomy position the perineum  was cleaned using Betadine 
solution. The bladder was  initially emptied using a metal catheter and then catheterized using 16 
Fr Foleys catheter and the bladder bulb was inflated with 7 ml of contrast plus saline ( 2ml 
contrast and 5ml saline). The cervical os was identified and the uterus was sounded. It was 
progressively dilated.  The central tandem was first  introduced followed by  the two ovoid 
tandems. The vaginal packing was done initially posteriorly with   the packing gauze soaked in 
contrast. The rest of the vagina was then packed  with the same gauze which was soaked with 
betadine. After a satisfactory packing, a rectal marker was inserted for at least 10 cm into the 
rectal lumen. HDR brachytherapy was performed using HDR Nucletron Micro Selectron 
brachytherapy unit  using 192Ir source as remote after loading technique. Orthogonal AP and 
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lateral films were taken on the simulator with dummy sources and radiopaque  markers to 
identify the bladder and rectum. Simulation films were taken for all patients, and the dose was 
calculated on the treatment planning system. 
4.9 Prescription 
A dose of 7.2 Gy to point A weekly once fractionation using HDR brachytherapy. It was 
scheduled with a gap of 7 days from the previous brachytherapy or the last chemotherapy, after 
assessment of toxicity. It was applied weekly once for a period of 3 weeks.  
Dosimetry 
For patients treated using four field techniques, the dose distribution was done using the Plato 
treatment planning system. HDR brachytherapy dosimetry was calculated on the Plato treatment 
planning system using orthogonal films for each insertion. The rectal and bladder reference dose 
points were determined according to the International Commission of Radiation Units and 
Measurement Report 38, guidelines for rectal doses (ICRU rectal point). The dose at point A, the 
rectal reference point, bladder reference dose, and isodose distributions were calculated using 
computer-based software (Nucletron Plato System PSS, Version 3.7.7). 
 
 
 
 
4.10 Planned  Treatment Schedule 
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Week  Day  Radiation  Chemotherapy
1  1  External RT  Concurrent  Cisplatin 40 mg/m2 after assessment 
  2  External RT   
  3  External RT   
  4  External RT   
  5  External RT   
  6, 7  ‐‐‐   
2  8  External RT  Concurrent  Cisplatin 40 mg/m2 after assessment 
  9  External RT   
  10  External RT   
  11  External RT   
  12  External RT   
  13,14  ‐‐‐   
3  15  External RT  Concurrent  Cisplatin 40 mg/m2 after assessment 
  16  External RT   
  17  External RT   
  18  External RT   
  19  External RT   
  20,21  ‐‐‐   
4  22  External RT  Concurrent  Cisplatin 40 mg/m2 after assessment 
  23  External RT   
  24  External RT   
  25  External RT   
  26  External RT   
  27,28  ‐‐‐   
5  29  Brachytherapy  Assessment Under Anesthesia 
  30  External RT   
  31  External RT   
  32  External RT   
  33  External RT   
  34,35  ‐‐‐   
6  36  Brachytherapy  Assessment Under Anesthesia 
  37  External RT   
  38 – 42     
7  43  Brachytherapy  Assessment Under Anesthesia 
  44 ‐49     
8  50     
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Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Publish Date: December 12, 2003 
 
 
 GRADE 1 GRADE 2 GRADE 3 GRADE 4
DERMATITIS  Faint erythema or 
dry desquamation  
Moderate to brisk  
erythema; patchy moist  
desquamation, mostly confined 
to skin folds and creases; 
moderate edema  
Moist desquamation other 
than skin folds and creases; 
bleeding induced by minor 
trauma or abrasion  
Skin necrosis or  
ulceration of full thickness 
dermis; spontaneous  
bleeding from involved  
site  
VAGINAL 
DRYNESS  
Mild  Interfering with sexual function; 
dyspareunia;   
 
--- 
 
--- 
VAGINAL 
MUCOSITIS  
Erythema of the 
mucosa;  
minimal symptoms  
Patchy ulcerations;  
moderate symptoms or  
dyspareunia  
Confluent ulcerations;  
bleeding with trauma;  
unable to tolerate vaginal 
exam, sexual intercourse or 
tampon placement  
Tissue necrosis;  
significant spontaneous  
bleeding; life-threatening  
consequences  
PROCTITIS Minimal discomfort,  
intervention not 
indicated. 
Erythema of the 
mucosa  
Symptomatic, medical  
intervention indicated but not 
interfering with ADL; Patchy 
ulcerations or  
Pseudomembranes  
Stool incontinence or other 
symptoms interfering with 
ADL Confluent ulcerations or 
pseudo membranes;bleeding 
with minor trauma  
Symptom associated with life 
threatening consequences  
Tissue necrosis;significant 
spontaneous bleeding; life 
threatening consequences  
CYSTITIS  Asymptomatic  Frequency with dysuria;  
macroscopic hematuria  
Transfusion; IV pain 
medications; bladder  
irrigation indicated  
Catastrophic bleeding;  
major non-elective  
intervention indicated  
BLADDER SPASMS Symptomatic, no 
intervention  
Symptomatic, antispasmodics 
indicated  
Narcotics indicated  Major surgical  
intervention indicated  
ENTERITIS  Asymptomatic,pathol
ogic or radiographic 
findings Only  
Abdominal pain; mucus  
or blood in stool  
Abdominal pain, fever,change 
in bowel habits with ileus; 
peritoneal signs  
Life-threatening 
consequences (perforation, 
bleeding,ischemia, necrosis)  
DIARRHOEA  Increase of <4 stools 
per day over base 
line; mild increase in 
ostomy output  
compared to base 
line  
Increase of 4 – 6 stools per 
day over base line; IV fluids 
indicated <24hrs; moderate 
increase in ostomy output 
compared to base line; not 
interfering with ADL  
Increase of ≥7 stools per day 
over baseline; incontinence; 
IV fluids ≥24hrs 
hospitalization, increase in 
ostomy output compared to 
baseline; interfering with ADL 
Life-threatening  
consequences (e.g.,  
hemodynamic collapse)  
ABDOMINAL 
PAIN  
Mild pain not 
interfering with 
function  
Moderate pain; pain interfering 
with function, but not 
interfering with ADL 
Severe pain; pain or  
analgesics severely  
interfering with ADL  
Disabling  
NEURO  
TOXICITY 
  
Asymptomatic, 
weakness  
on exam/testing only  
Asymptomatic; loss 
of deep tendon 
reflexes or  
Symptomatic weakness  
interfering with function, but 
not interfering with ADL. 
Sensory alteration or  
paresthesia (including  
tingling)  
Weakness interfering with 
ADL; bracing or assistance to 
walk (e.g.,cane or walker) 
indicated Sensory alteration 
or paresthesia interfering  
with ADL  
Life-threatening; disabling 
(e.g., paralysis)  
 
ALLERGY  Transient flushing or 
rash; drug fever 
<38°C (<100.4 F)  
Rash; flushing; urticaria; 
dyspnea; drug fever ≥38°C 
(≥100.4°F)  
Symptomatic bronchospasm, 
with or without urticaria;  
parenteral medication(s)  
indicated; allergy-related 
edema / angio edema; 
hypotension 
Anaphylaxis  
EMESIS  1 episode in 24 hrs  2 – 5 episodes in 24 hrs; IV 
fluids indicated <24 hrs  
≥6 episodes in 24 hrs; IV 
fluids, indicated ≥24 hrs  
Life-threatening  
Consequences  
NAUSEA  Loss of appetite 
without alteration in 
eating habits  
Oral intake decreased  
without significant weight loss, 
dehydration or malnutrition; IV 
fluids indicated <24 hrs  
Inadequate oral caloric or 
fluid intake; IV fluids, tube 
feedings, or TPN  
indicated ≥24 hrs  
Life-threatening  
consequences  
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FEBRILE 
NEUTROPENIA  
(fever of unknown 
origin without 
clinically or micro 
biologically 
documented 
infection) (ANC 
<1.0 x 109/L, fever 
≥38.5°C)  
----  ----  Present  Life-threatening  
consequences (e.g.,  
septic shock,  
hypotension, acidosis,  
necrosis)  
REMARK: Fever with Grade 3 or 4 neutrophils in the absence of documented infection is graded as Febrile neutropenia (fever of 
unknown origin without clinically or microbiologically documented infection).  
INFECTION  
(documented 
clinically or  
microbiologically) 
with Grade 3 or 4 
neutrophils (ANC 
<1.0 x 109/L)  
 Localized, local intervention 
indicated 
IV antibiotic, antifungal, or 
antiviral intervention  
indicated; interventional  
radiology or operative  
intervention indicated  
Life-threatening  
consequences (e.g.,  
septic shock,  
hypotension, acidosis,  
necrosis)  
Infection with 
normal ANC or 
Grade 1 or 2  
Neutrophils 
 Localized, local 
intervention indicated  
IV antibiotic, antifungal, or 
antiviral intervention  
indicated; operative  
intervention indicated  
Life-threatening 
consequences (septic shock, 
hypotension, acidosis,  
necrosis) 
Infection with 
unknown ANC  
 Localized, local 
intervention indicated  
IV antibiotic, antifungal, or 
antiviral intervention  
indicated; operative  
intervention indicated  
Life-threatening  
consequences (e.g.,  
septic shock, hypotension, 
acidosis, necrosis)  
Alopecia Thinning or patchy Complete   
Fever(F) 100.4 to 102.2 102.3 to 104.0 104.0 for <= 24 hours 104.0 for > 24 hours 
Fatigue Mild Moderate, causing difficulty 
performing some ADL 
Severe, interfering with ADL Disabling 
Insomnia Occasional difficulty 
sleeping 
Difficulty sleeping interfering 
with function 
Frequent difficulty sleeping 
interfering with ADL 
Disabling 
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4.11 Assessment of toxicity 
All patients were  assessed for toxicity every week as per the planned schedule using RTOG / 
CTCAE version 3.0 assessment tool. They were examined and their symptoms noted.  They were 
carefully examined for a any radiation induced or chemotherapy causing toxicity which  were  
then documented.  The blood tests done were reviewed and then decided whether to proceed with 
chemotherapy.  If  there was  any Grade III and above toxicity as per the assessment, then 
chemotherapy  and  radiation was deferred and appropriate treatment  initiated.  The response to 
the treatment started were closely monitored. 
 4.12 Assessment for brachytherapy 
At 36 Gy the patients were assessed for the feasibility of interdigitating brachytherapy.  If the 
tumor response was adequate and intracavitary feasible the first fraction of brachytherapy was 
given at 40 Gy followed by weekly once fraction for three weeks.  If the tumor response is not 
adequate, reassessment was done  again after one week  for the feasibility of application of 
brachytherapy.  If there was still an inadequate response of the tumor and brachytherapy not 
feasible then external radiotherapy was continued with smaller fields till completion.   
Treatment time: Overall treatment time (OTT) was taken from the first day of external 
radiotherapy to the last day of brachytherapy. The reasons for treatment delay were noted. 
4.13 First follow up evaluation 
The first follow up was done after 6 weeks. History of all the complaints and a thorough clinical 
examination is done.  The clinical evaluation was done to assess the tumor response as well as 
any toxicity.   
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4.14 Statistical Analysis 
A descriptive analysis and frequency distribution of the patient characteristics was done. 
Frequency distribution was done to assess the toxicities. Anova and Chi –Square tests was done 
to see if there was any associated factor which can be related to inadequate tumor response to the 
treatment given. 
Ethical Consideration 
The institutional Review Board (IRB) had considered the study in its ethics committee and 
cleared the same before the study was started. 
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V  RESULTS 
From the month of May 2009 to November 2009, 72 patients were newly registered with the 
diagnosis of carcinoma cervix. Some were referred cases, some were treated elsewhere and come 
for follow up and some came only for evaluation and confirmation of diagnosis. 
Among these patients 39 were evaluated for treatment and screened for eligibility to be included 
in the study out of which 27 patients were enrolled after their informed consent. 
Four of these patients have not completed the therapy therefore not included in the analysis.  
Following enrollment 4 patients withdrew from the study; another 2 defaulted while 1 patient 
was a screen failure. 
5.1 Patient turnout 
16 patients completed their treatment by the end of November out of which 3 patients did not 
undergo brachytherapy due to inadequate response and therefore were not fit for brachytherapy. 
Out of the remaining 13 patients, 8 patients could undergo brachytherapy interdigitating with 
external radiotherapy while 5 patients could undergo this only after the completion of external 
radiation therapy. 
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Figure‐1: This shows the pictorial representation of the turnouts of all the patients who have signed the 
consent form. 
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The following table shows the patient characteristics. 
Table-1: Patient Characteristics-History 
Age  Occup  BPV  PCB  WDPV  Abd 
pain 
Back 
pain 
Mar/ 
Wid 
Pre/ 
Meno 
Gra  Par  Liv  Abo  Diseases 
48  TEACH  180  0  30  0  0  Married  Pre  3  3  3  0   
52  HWIFE  30  0  365  0  0  Married  Meno  6  6  5  0   
45  HWIFE  150  150  60  0  0  Married  Meno  3  3  3  0   
43  HWIFE  180  360  180  0  0  Married  Meno  4  4  4  0   
48  TEACH  180  0  0  0  30  Married  Pre  3  3  3  0   
59  HWIFE  90  0  0  0  0  Widow  Meno  6  6  6  0  HT,EPILEPSY 
52  HWIFE  60  0  0  60  60  Married  Pre  3  2  2  1  RHEU  ARTH 
48  HWIFE  150  0  150  30  150  Married  Pre  2  2  2  0   
47  HWIFE  240  1  120  0  0  Married  Meno  5  5  3  0   
41  HWIFE  120  30  120  0  0  Married  Pre  2  2  2  0   
38  HWIFE  60  0  0  0  0  Married  Pre  5  4  3  1   
30  HWIFE  90  0  0  90  0  Married  Pre  1  1  1  0   
35  HWIFE  0  15  0  0  0  Married  Meno  4  3  2  1  OTOSCLER 
 
Legend 
Age in years,  Occup‐Occupation: House wife/ Teacher ,   BPV‐ Bleeding Per Vaginum in days ,  PCB‐ 
Post Coital Bleeding in days  ,  WDPV‐White Discharge Per Vaginum in days ,  Abdominal Pain in days ,  
Back pain in days  ,  Marital status: Married / Widowed  ,  Menstrual Status: Menopausal/ Pre‐
menopausal  ,  Gra‐Gravida  ,  
 Par‐Parity, Liv‐Live, Abo‐Abortion, HT‐ Hypertension, RHUE ARTH‐ Rheumatoid Arthritis,  
OTOSCLER‐ Otosclerosis 
 
 
5.2 Patient characteristics 
It can be seen that except for two teachers, all of them were housewife in their occupation. All of 
them were married and one is a widow.  Seven of them were premenopausal women. 
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5.2.1 History- None of the patients had complaints of dyspareunia, fever, and fatigue at the start 
of treatment. None of them had any bladder or bowel complaints. 
One patient was a hypertensive and also had a history of seizure disorder while another   had 
Rheumatoid Arthritis and the third patient had Otosclerosis. There was no one with the history of 
Diabetes, Ischemic Heart Disease or Tuberculosis. 
Table 2:  Description of presenting Complaints 
Parameter Number Minimum  
(days) 
Maximum 
(days) 
Mean (days) 
Bleeding PV 12 30 240 127.50 
Post Coital Bleed 5 1 360 111.20 
White Discharge PV 7 30 365 146.43 
Abdominal pain 3 30 90 60.00 
Back Pain 3 30 150 80.00 
 
Except for one patient, all of them presented with bleeding per vaginum. Five of the patients 
complained of post coital bleeding.  Seven of them had white discharge per vaginum. Only three 
of them complained of lower abdominal pain or low backache. 
 
 
5.2.2 Examination findings 
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The general examination showed that all patients had good performance score. None of them had 
clinically evident pallor. Their systemic examination was within normal limits except for one 
who had tricuspid regurgitation. None of them had any handicaps or any deformities. 
The table below shows the relevant findings in the pelvic examination. 
Table 3: Examination findings showing the region involved by the tumor. 
Region involved Number 
Fornix-Anterior 6 
Fornix –Posterior 7 
Fornix-Rt  Lateral 6 
Fornix-Lt  Lateral 10 
Vagina  Upper two thirds 9 
Vagina  Lower third 0 
Parametrium  Not up to side walls 11 
Parametrium   up to side walls 2 
Cervix both lips 13 
Bladder and Rectum 0 
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Table 4: Clinical staging 
 
Stage  
Frequency Percent 
Cumulative 
Percent 
 2B 11 84.6 84.6 
3B 2 15.4 100.0 
Total 13 100.0  
 
5.2.3 Clinical stage- Except for 2 of the patients who were stage III B,  all of them belonged to 
stage II B. 
5.2.4 Investigation findings 
All of the patients had their biopsies reported by the pathologists in CMC as squamous cell 
carcinoma. Their subtypes are shown as follows: 
Table 5: Sub types of Squamous cell carcinoma-histology 
 
 
Majority of the patients had moderately differentiated carcinoma, 2 reported as non keratinizing 
squamous cell carcinoma while 4 had poorly differentiated carcinoma.  
 Histology 
Frequency Percent 
Cumulative 
Percent 
 Poorly differentiated 4 30.8 30.8 
Moderately  differentiated 7 53.8 84.6 
Non keratinizing 2 15.4 100.0 
Total 13 100.0  
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Radiological tests with USG and Chest X ray did not reveal any metastatic lesions elsewhere in 
the body. There were no other abnormalities detected in the lung, liver or kidney. 
5.3 Hematological toxicity 
Hemoglobin- 3 patients had a drop in Hb while on treatment needing blood transfusion.  
Platelets- 3 patients had a drop in platelet count below 0ne lakh while on treatment and it 
resulted in delay of the overall treatment time. 
LFT - The liver enzymes were found to be normal throughout the treatment.  
Creatinine clearance dropped below 50 in two patients needing a delay in the treatment with 
chemotherapy. One patient had persistently low creatinine clearance and chemotherapy was 
given with dose modification as per Avon, Somerset and Wiltshire Cancer Services (ASWCS) 
guideline. 
Table 6: Neutropenia  
Absolute Neutrophil 
Count 
Number of 
patients 
Grade III 3
Grade IV 4
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Absolute Neutrophil Count- Seven patients had a significant reduction in neutrophil counts. 
Three patients developed Grade III toxicity   and four developed Grade IV toxicity. This was one 
of the important factors causing the delay in overall treatment time.  
5.4 Gastrointestinal toxicity 
Table 7: Complaint of nausea 
Nausea Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 5 62 73.81 73.81 
Grade 1 7 21 25 98.81 
Grade 2 1 1 1.19 100 
 
Eight patients had complaints  of nausea out of the 13 after treatment with radiation and 
chemotherapy. There were 22 episodes of complaints of nausea. However there were only 3 
episodes of complaints of vomiting. 
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Table 8: Incidence of diarrhea and abdominal pain 
Diarrhea Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 6 73 61.32 61.32 
Grade 1 4 8 7.67 68.99 
Grade 2 3 3 2.56 100 
Abdominal 
pain 
Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 6 71 84.52 84.52 
Grade 1 7 13 15.48 100 
 
Seven patients had diarrhea and 7 had abdominal pain. Occurrence of loose stools was one of the 
factor to cause a delay in the treatment plan causing a lengthening in the overall treatment time 
for one patient. 
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5.5 Non hematological toxicity 
Table 9: Occurrence of Vaginal mucositis and dermatitis. 
Vaginal 
mucositis 
Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 3 67 75.28 75.28 
Grade 1 5 14 15.73 91.01 
Grade 2 1 2 2.25 93.26 
Grade 3 4 6 6.74 100 
Dermatitis Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 3 59 66.29 66.29 
Grade 1 4 17 19.1 85.39 
Grade 2 2 7 7.87 93.26 
Grade 3 4 6 6.74 100 
 
 
Delay of the completion of the treatment occurred due to   grade 3 radiation dermatitis and 
vaginal mucositis.   Grade III reaction occurred in 4 patients needing a break in the treatment. 
There were 6 episodes of grade 3 and 24 episodes of Grade I and Grade II toxicity.  
Below is a distribution of  radiation dermatitis and vaginal mucositis  with the radiation dose 
received. 
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 It can be seen that radiation dermatitis and vaginal mucositis is seen to be related to the radiation 
dose received.  
5.6 Other toxicities.  
 
Table 10: Complaints of fatigue and insomnia 
Fatigue Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 4 62 73.81 73.81 
Grade 1 9 22 26.19 100 
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Insomnia Number of 
patients 
Frequency Percent Cumulative 
percent 
Absent 6 68 80.95 80.95 
Grade 1 7 16 19.05 100 
 
One complaint which occurred but did not  cause a delay in the treatment was fatigue. There 
were 22 episodes of fatigue. 
There was no complaint of allergy, alopecia, neurotoxicity at any given time. 
5.7 Treatment delays  
Table 11: Reasons for delay in the planned treatment in each week. 
Week Reasons for delay in planned treatment 
First Low platelets 
Second Loose stools, Increasing  Creatinine 
Third Loose stools, Urinary Infection, neutropenia, 
Low Creat clearance,Low platelets 
Fourth Neutropenia, Machine repair, Loose stools, Low 
platelets, Bleeding PR, Urinary infection, fever, 
Grade III radiation induced dermatitis and 
vaginal mucositis 
Fifth Persistent neutropenia, Grade III radiation 
induced dermatitis and vaginal mucositis 
reaction in vulva, fever 
Sixth and above Persistent Neutropenia, Low platelets, 
Grade III radiation induced  Vulval Reaction 
and vaginal mucositis 
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The reasons for delay in chemotherapy in each week are as follows: 
In the first week one patient could not be started on chemotherapy on day 1 due to low platelet. 
In the second week 1 patient did not get chemotherapy on time due to the complaint of loose 
stools associated with increasing creatinine level.  
In the third week loose stools were the cause of delay in 3 patients while low counts associated 
with urinary infection was seen in one patient. Two patients had low platelets and another two 
patients had low creatinine clearance interfering in the treatment. 
In the fourth week, loose stools were seen in 2 patients, decreased counts in one patient. One 
each had complaints of Grade III radiation induced dermatitis and vaginal mucositis, low 
platelets, bleeding per rectum, and infection causing the delay.  One day delay was caused due to 
machine repair. 
By the fifth week many patients had delay due to multiple reasons. Neutropenia alone was seen 
in 6 patients, radiation induced dermatitis and vaginal mucositis in 3 patients, one patient had 
neutropenia with radiation induced dermatitis and vaginal mucositis. One patient had neutropenia 
with thrombocytopenia. One patient had fever along with low counts. One day delay was found 
in one patient due to theatre unavailability. 
From the sixth week onwards significant delays were caused by persistent neutropenia (one 
patient), low platelets (one patient), and radiation induced dermatitis and vaginal mucositis(one 
patient). One day delay was found in one patient due to theatre unavailability. 
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5.8 Overall treatment time 
Table 12: Time for treatment completion and reasons for delay. 
 
8 weeks 9 weeks ¾ 9weeks 
4 5 4 
Reasons Neutropenia(3) 
Grade III RT 
reaction(2) 
 
Neutropenia(2) 
Thrombocytopenia(1) 
Grade III RT reaction(1)
Loose stools(1) 
 
Four patients completed their treatment within  8 weeks time,  5 completed  in 9 weeks. Of  these 
5 patients, 3 had prolonged neutropenia while the other 2 had radiation induced dermatitis and 
vaginal mucositis  causing the delay in their completion of their treatment. 
Four patients took longer than 9 weeks to complete their treatment due to persistent neutropenia 
(one patient), thrombocytopenia (one patient), and Grade III radiation induced dermatitis and 
vaginal mucositis (one patient) and loose stools with neutropenia (one patient). 
5.9 Failure to interdigitate brachytherapy 
The following are the reasons why brachytherapy could not be interdigitated in 5 patients and 
brachytherapy application not done in the other 3 patients - 
Two patients had Grade III radiation induced dermatitis and vaginal mucositis not allowing 
brachytherapy application. 
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One patient had persistent neutropenia causing the delay in the procedure.  
The other 2 patients did not have adequate response to the chemoirradiation already given. 
3 patients did not have any brachytherapy at any time due to inadequate response to the radiation 
even at the end of 50 Gy.  
The following is a pictorial representation to show the treatment given. 
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  Period of treatment 
 
 
   ‐‐‐   Fraction of brachytherapy    
 
     ‐‐‐   Cycle of chemotherapy 
 
FIGURE 2: This figure is a pictorial representation of the treatment received by the patients.  The 
chemotherapy received and the brachytherapy applications are shown. (Not to scale). 
 
 
5.10 Treatment response in relation to other parameters 
An analysis was done for all 16 patients to see if there is any relation with response to the 
treatment at 40 Gy as evaluated clinically with other factors. 
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The following tables show the significance of the relationship between these factors and the 
response to treatment as clinically assessed at 40 Gy. 
Table 13: Multivariate Analysis of Outcome (as assessed clinically- response at 40 Gy) and 
clinical and biochemical parameters. 
PARAMETER F VALUE P Value (2 
tailed) 
HB ANY TIME LESS THAN 10 .017 .898 
BASELINE  HB 1.007 .333 
BASELINE WEIGHT .021 .886 
MAX. LOSS OF WEIGHT 1.523 .239 
TECHNIQUE  2D/3D .884 .363 
ANYTIME CREATININE CL. < 55 .131 .723 
EVERYTIME CREATININE CL.>60 .131 .723 
AGE .345 .566 
HISTOLOGICAL SUB TYPES .579 .459 
NUMBER OF CHEMOTHERAPY 1.916 .188 
 
64 
 
The factors which were taken into account were baseline Hemoglobin, anytime Hemoglobin less 
than 10, baseline weight and loss of weight, creatinine clearance less than 55 anytime against 
always above 60, clinical stage, technique of treatment 2D versus 3D, the age of the patient, the 
differentiation of the tumors as well as the total number of chemotherapy received.  
Table 14: Analysis of Outcome (as assessed clinically- response at 40 Gy) and histological sub 
type of squamous cell carcinoma. 
HISTOLOGY 
SUB TYPE 
RESPONSE Total 
NO YES 
Poorly 
differentiated 
1 4 5 
Moderately  
differentiated 
3 6 9 
Non 
keratinizing 
1 1 2 
Total 5 11 16 
P  VALUE ( 2 TAILED)= 0.640 
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5.10.1 Relation to histological Sub type -Analysis was done to see if the response is related to 
the histological Sub type, whether poorly differentiated is more responsive compared to the well 
differentiated. There were 5 poorly differentiated type of squamous cell carcinoma and 9 
moderately  differentiated  squamous cell carcinoma. However the test did not show any 
significance. 
Table 15: Analysis of Outcome (as assessed clinically- response at 40 Gy) and technique of 
radiation conventional (2D) and conformal (3D). 
RADIATION 
TECHNIQUE 
RESPONSE Total 
NO YES 
conventional(2D) 4 6 10 
conformal(3D) 1 5 6 
Total 5 11 16 
P  VALUE ( 2 TAILED)= .950 
5.10.2 Relation to  technique of radiation -With the onset of  more and more sophistication,  
and  more people affording and opting for the conformal radiation therapy over the conventional 
form of radiation, an analysis was done to see if the response of the tumor was in any way related 
to the technique used. There were 10 patients treated with conventional 2D technique and 6 
patients treated with conformal 3D technique.  It did not show any significance. 
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Table 16: Analysis of Outcome (as assessed clinically- response at 40 Gy) and number of cycles 
of chemotherapy received. 
NUMBER OF 
CHEMOTHERAPY 
RESPONSE Total 
NO YES 
2 0 2 2 
3 1 4 5 
4 4 5 9 
Total 5 11 16 
P  VALUE (2 TAILED)= 1.933 
5.10.3 Relation to number of chemotherapy -Response of the tumor with respect to  total 
number  of chemotherapy received by the patient was looked at. Two patients had received 2 
cycles of chemotherapy with cisplatin, 5 patients had received three and the remaining 9 had 
received 4 cycles of chemotherapy respectively.  It was analyzed  and found that there was no 
significance seen. A T test was also done.  Test of significance was done for factors such as  
baseline Hemoglobin, anytime Hemoglobin less than 10, baseline weight and loss of weight, 
creatinine clearance less than 55 anytime against always above 60  and no significant results was 
found. 
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VI   DISCUSSION  
Cervical cancer remains a significant health problem for developing countries. Multiple trials 
have clearly indicated that platinum based concurrent chemoirradiation should be the first line 
treatment for carcinoma cervix. They again confirmed the addition of cisplatin showed the 
superiority of chemo irradiation with an absolute survival benefit of 12 % at the end of 5 years.49 
Therefore the standard treatment for carcinoma of cervix stage 2 and 3 is a combination of 
external beam radiotherapy with once weekly concurrent chemotherapy using Cisplatin and 
brachytherapy. Usually brachytherapy done in cancer cervix is low-dose-rate (LDR). With the 
advent of the high-dose-rate brachytherapy, low dose rate brachytherapy has been replaced by 
the high dose rate brachytherapy (HDR). The potential disadvantages like long treatment time, 
radiation exposure to the health professionals, hospitalization for therapy, the associated risks of 
anesthesia, thromboembolism due to prolonged bed immobilization, prolonged discomfort of 
vaginal packing, potential chance of displacement of the applicators etc were overcome with 
HDR application. 
The members of the American Brachytherapy Society50 who are experts in HDR cervical 
brachytherapy recommend HDR brachytherapy over the LDR in cancer of the cervix due to the 
following advantages. 
1. The radiation exposure hazard for caregivers, visitors and other personnel are eliminated while 
preparing the source and while it is being transported. 
2. It reduces the treatment times thereby causing  
a) decreased patient discomfort as prolonged bed rest is eliminated. 
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b) It is possible to treat patients who may not tolerate long periods of isolation and those who are 
at high risk for deep vein thrombosis. 
c) As the patient is more comfortable and more compliant there is lesser risk of applicator 
movement during therapy. 
d) Patients can be treated as Outpatient thereby reducing hospitalization leading to lesser 
expenses. 
e) There is possibility of greater displacement of critical organs either by packing or by using 
rectal retractor, thereby reducing rectal and bladder morbidity. 
f) The number of patients being treated can be increased due to the time saving and other 
conveniences thereby optimizing the facilities of institutions in some developing countries. 
3. It allows the use of smaller diameter sources than those used in LDR: 
a) The need for dilatation of the cervix is reduced thereby reducing the need for heavy sedation 
or general anesthesia. 
b) High-risk patients for general anesthesia can now be more safely treated. 
c) Easier insertion of applicators into the cervix. 
4. Makes dose distribution optimization possible. The variation of dwell time with source allows 
greater control of the dose distribution and potentially less morbidity. 
5. Allows interdigitation of external radiation with brachytherapy which can lead to a shorter 
overall duration of treatment and potentially better tumor control. 
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 Further; randomized trials by Shigematsu et al and Patel et al have demonstrated that HDR 
brachytherapy is an equal alternative to conventional low-dose-rate brachytherapy in the 
treatment of uterine cervical carcinoma.51  Also a major advantage of HDR brachytherapy is 
ooptimization of dose distribution with better control of the dose distribution and potentially less 
morbidity. Occurrence of potential late toxicities that are associated with large dose per fraction 
is one of the main disadvantages of HDR brachytherapy but this can be overcome with adequate 
fractionation. Trials have shown that reduced overall treatment time is one of the factors that 
influences cure of cervical cancer. With HDR brachytherapy interdigitation with external beam 
radiotherapy is possible which could lead to a shorter overall treatment time and therefore 
possible better tumour control.  
 A wide variety of fractionation regimes have been tried with high dose rate brachytherapy to 
achieve reduced treatment time for the purpose of reducing the mortality. Results of various 
trials indicate that one practical option which was feasible with high dose rate brachytherapy 
which was not possible with low dose rate brachytherapy was to interdigitate the brachytherapy 
along with external radiotherapy.  In our study this was done after 4 weeks of external beam 
radiotherapy with concurrent 4 cycles of weekly regimen of Cisplatin.  
No clear consensus of the appropriate number of fractions or the dose per fraction has been 
reached. Various fractionation schemes have been used experimentally in search of the optimal 
technique. The American Brachytherapy Society recommends fraction size of _7.5 Gy using four 
to eight fractions of HDR brachytherapy but recognizes that there is insufficient data to clearly 
recommend any one regime in favor of others due to lack of experience.2  In this study 7.2 Gy 
weekly once regime for 3 weeks was used.  
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Most of our patients had stage 2b carcinoma cervix with proliferative growths and had good 
performance status.  All of them had squamous cell carcinoma which is the most common type.  
Their main presenting complaints were bleeding PV, white discharge PV and post coital 
bleeding. Few of them had backache or abdominal pain. None of them had bleeding severe 
enough to undergo any blood transfusion or immediate intervention. None of them had any 
complaints related to bladder or rectum. Among the patients included in the study 6 of them 
underwent conformal radiation therapy. 
Only one patient had hypertension and seizure disorder and another had Rheumatoid Arthritis 
while the third patient had Otosclerosis. There was no other co morbid systemic illnesses among 
the remaining patients.  
 Sood et al  have reported that although concomitant chemotherapy with pelvic irradiation has 
improved survival among patients with locally advanced carcinoma of the cervix, most patients 
(93%) who received chemotherapy suffered from acute toxicity, including hematologic toxicity, 
gastrointestinal toxicity and deep venous thrombosis. But the actuarial incidence of late toxicity 
was however only 6%.52 
The toxicity due to chemotherapy with radiation were mainly severe neutropenia followed by 
thrombocytopenia in our patients. About half of our patients developed hematological acute 
toxicity.  Nausea and loose stools were also commonly seen. These toxicities were seen to delay 
the overall treatment time. A recent meta-analysis on toxicity following radiation alone or in 
combination with chemotherapy for locally advanced cervical cancer confirmed that concurrent 
chemotherapy increases acute toxicity – gastrointestinal and hematologic – as compared with 
radiation alone53. The toxicity seen by the time of assessment for brachytherapy was mainly due 
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to concurrent chemoirradiation. In our study, 3 patients had grade 3 radiation induced dermatitis 
and vaginal mucositis causing delay in the overall treatment time while another 3 developed 
grade 3 neutropenia and 4 had grade 4 neutropenia causing a delay. One patient had Urinary 
infection which required hospitalization and caused a delay in chemotherapy as well as radiation 
therapy. Acute Gastrointestinal toxicity was common though not severe enough to cause major 
interruptions in the treatment in all our patients except one. However late effects of 
chemoirradiation needs to be carefully monitored as suggested in literature54. 
Overall, 6 patients had completed 4 cycles of chemotherapy, the others could not due to 
hematologic or renal toxicity. All of them except two received at least three cycles.  
Although there is literature reporting the use of 6 cycles of concurrent chemotherapy along with 
radiation therapy55, we have used only four cycles in our study because of the problems of low 
blood counts, and potential delay in brachytherapy if more number of chemotherapy is given. 
 The overall treatment time was seen to range from 51 days to 77 days. 4 patients completed 
within 8 weeks and another 5 within 9 weeks. The other 4 patients took more than 9 weeks to 
complete the treatment due to persisting neutropenia, thrombocytopenia and radiation induced 
dermatitis and vaginal mucositis. One of them had loose stools causing the delay.  
The response to treatment was assessed clinically at the end of 40 Gy with a view of 
consideration for the application of brachytherapy. It was seen that response was more in the 
poorly differentiated than in the moderately differentiated tumors even though it was not found 
to be statistically significant. It was also seen that the response among the conformal group was 
more when compared to the conventional technique of radiation. There was no apparent benefit 
seen in response due to the increased number of chemotherapy received.  However all these 
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parameters when checked for any statistically significance did not reveal any significant 
difference. 
Analysis done to see if there is any relation with response to the treatment at 40 Gy as evaluated 
clinically with factors like baseline Hemoglobin, anytime Hemoglobin less than 10, baseline 
weight and maximum loss of weight, creatinine clearance less than 55 anytime against always 
above 60, clinical stage, technique of treatment 2D versus 3D, the age of the patient, the 
differentiation of the tumors as well as the total number of chemotherapy received did not show 
any significant result. The reason a difference was not seen may  be due to the less number of 
patients in the study. 
Among the 16 patients for 3 patients brachytherapy was not feasible due to inadequate response 
to the radiation and therefore were not included in the overall analysis. 
Interdigitation with brachytherapy was done only in 8 out of the 13 patients who received 
brachytherapy.  The main reasons why brachytherapy could not be interdigitated in 3 of our 
patients were Grade III  radiation induced dermatitis and vaginal mucositis, persistent 
neutropenia and  while the other 2 patients did not have adequate response following 40 Gy 
radiation but brachytherapy was possible after completion of external beam radiotherapy. 
Therefore another option that could be  considered to reduce overall treatment time is to do 2 
brachytherapy applications instead of 3 applications with higher dose per fraction.  Another 
advantage of using fewer fractions is patient convenience and improved patient compliance. 
 Further trials are needed to get an ideal treatment plan so as to get the maximum benefit of 
chemotherapy as well as that of interdigitated brachytherapy. 
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Due to inadequate number of patients we need  to continue the study to find out the trends of 
tolerability, as well as documentation of late toxicity. There should be long term follow up for 
assessing the treatment outcome.  Various other regimes of different number of concurrent 
chemotherapy as well as the number of fractionations and the dose per fraction should be 
experimented and studied to get an optimum schedule which will allow us to get the maximum 
benefits of the concurrent chemotherapy as well as that of reaping the full advantage of the 
possibility of interdigitating HDR brachytherapy along with external radiotherapy so that overall 
treatment time is less than 8 weeks.  
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VII  CONCLUSIONS  AND RECOMMENDATIONS 
In this pilot project done to study the feasibility of interdigitating HDR brachytherapy with 
Concurrent Chemoirradiation in carcinoma cervix, it was found that there was acute toxicity - 
hematological toxicity, radiation induced dermatitis and vaginal mucositis which caused 
significant delay in the completion of the treatment.   
The various reasons for not being able to interdigitate brachytherapy with external beam 
radiotherapy was-- 
1. Grade 3 and 4 neutropenia 
2. Grade 3 radiation induced dermatitis and vaginal mucositis 
3. Inadequate response to concurrent chemoirradiation 
4. Acute radiation proctitis  
With the regime used in our study of 4 cycles of concurrent chemotherapy with cisplatin 40 
mg per square meter along with weekly once HDR brachytherapy of 7.2 Gy to point A 
interdigitating with external radiotherapy only 4 of the 13 patients completed within 8 weeks 
and none of them completed within the planned 7 weeks. So a reduction in overall treatment 
time that was aimed for could not be achieved. 
Another option that could be tried is to carry out 2 brachytherapy applications with higher 
dose instead of the 3 fractions as used in this study with  a better tolerance and possibility of 
reducing the overall treatment time. Another advantage of using fewer fractions of 
brachytherapy would be patient convenience and improved patient compliance. 
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APPENDIX 
PROFORMA   
Patient  Characteristics 
Name   : 
Age  : 
Hospital No :     RT NO: 
Address : 
 
Contact  No : 
Occupation : 
Presenting Complaints : 
1. Bleeding  PV                  Yes (1)/  No (2)  Duration 
2. Post Coital Bleeding  Yes (1)/  No (2)     Duration 
3. White discharge PV  Yes (1)/  No (2) Duration  
4. Lower  Abdominal pain     Yes (1)/  No (2)        Duration      
5. Low  Backache         Yes (1)/  No (2)         Duration      
6. Fever                                      Yes (1)/  No (2)      Duration      
7. Dyspareunia                         Yes (1)/  No (2)      Duration              
8. Fatigue                                  Yes (1)/  No (2)      Duration      
9. Bladder Symptoms               Yes (1)/  No (2)      Duration      
a. Dysuria…….. 
b. Frequency……. 
c. Burning…… 
d. Hematuria…… 
e. Incontinence…. 
10. Bowel  Symptoms              Yes (1)/  No (2)             Duration      
a. Bleeding…….. 
b. Pain……. 
c. Frequency.… 
Marital Status:  1) Single 2) Married 3)  Widow 4) Divorced 
Menstrual  Status :      Premenopausal (1) / Post menopausal (2)               Menarche… 
Obstetrics              G   P   L   A 
   First  Child Birth… 
   Last  Child Birth… 
Other Diseases        1 – DM   2 – HT  3 – TB  4 – IHD 5 – Others 
Examination 
ECOG          Ht       Wt        BSA 
CVS Normal (1)/ Abnormal (2) 
RS Normal (1)/ Abnormal (2) 
CNS Normal (1)/ Abnormal (2) 
Abd Normal (1)/ Abnormal (2) 
Pelvic   Examination: 
a) External  Genitalia 
b) Cervix            Anterior lip     Posterior lip 
c) Fornix           Anterior   Posterior   Right    Left 
d) Vagina         Upper  2/3 Anterior   Posterior   Right    Left 
Lower  1/3 Anterior   Posterior   Right    Left 
e)  Parametrium   Right side        Not  upto  pelvic  wall/  Upto  pelvic wall 
Left side         Not  upto  pelvic  wall/  Upto  pelvic wall 
f) Rectal mucosa 
Proctoscopy- 
Cystoscopy- 
Diagnosis                                        Stage 
Investigations 
1. Pathology   
a. Biopsy  1. Squamous cell carcinoma 2. Adeno carcinoma 3. Others 
b. Differentiation 1.  Poor 2.  Moderate 3.  Well 
2. Blood tests  Hb    TC    DC      Platelets Creatinine    LFT 
3. USG   Normal (1)/ Abnormal (2) 
4. Cxr   Normal (1)/ Abnormal (2) 
TREATMENT:  
CHEMOTHERAPY:  Weekly Cisplatin Dose : 40 mg/m2 = ………………..mg  
Week RT dose 
(Gy) 
completed 
Proposed 
brachytherapy / 
chemotherapy dates 
Actual 
brachytherapy / 
chemotherapy dates 
Reason for delay 
  Dates Day Dates Day  
1       
2       
3       
4       
5       
6       
7       
8       
Delay between the first and second cycle :  
Delay between the second and third cycle :  
Delay between the third and fourth cycle :  
No. of chemotherapy cycles completed :  
 
Delay between the first and second fraction of HDR brachytherapy :  
Delay between the second and third fraction of HDR brachytherapy :  
No. of brachytherapy applications completed :  
 
Assessment at 40 Gy: 
External Beam Radiation Therapy :  
Machine: Cobalt / Linac 
 
Energy used: Co -60 , 6MV , 15 MV 
 
Dose / Fractionation :  
 
EBRT - Treatment Time : From 
…………………..………….To……………….…………………  
 
EBRT - Duration of Treatment: ...………………weeks ………….….....Days  
 
Duration of Breaks during EBRT:  
 
Week 1: ……………….……………………….Days  
Week 2: ……………….……………………….Days  
Week 3: ………………….…………………….Days  
Week 4: ………………….…………………….Days  
Week 5: ………………….…………………….Days  
Week 6: ………………….…………………….Days  
Week 7: ………………….…………………….Days  
Week 8: ………………….…………………….Days  
 
Total days of breaks during EBRT: ………….. Days  
 
Reason for the delay:  
 
Brachytherapy :                                                        Dose 
 
 First fraction Second fraction Third fraction 
Date of Application    
Point A Dose    
Point B Dose    
Bladder Dose    
R1 dose    
R2 dose    
R3 dose    
Mean Rectal dose    
FOLLOW UP AFTER  6  WEEKS OF COMPLETION OF TREATMENT: 
 
 
1. Symptoms :  
 
2. Performance status : ECOG ………………………………………………………..  
 
3. Physical Parameters : Height……………Weight………………BSA..……………  
 
4. System Examination :  
 
CVS Normal (1)/ Abnormal (2) 
RS Normal (1)/ Abnormal (2) 
CNS Normal (1)/ Abnormal (2) 
Abd Normal (1)/ Abnormal (2) 
 
 
Pelvic   Examination: 
a) External  Genitalia 
b) Cervix            Anterior lip     Posterior lip 
c) Fornix           Anterior  Posterior  Right  Left 
d) Vagina         Upper  2/3        Anterior  Posterior  Right  Left 
Lower  1/3        Anterior  Posterior  Right  Left 
e) Parametrium    Right side        Not  upto  pelvic  wall/  Upto  pelvic wall 
Left side         Not  upto  pelvic  wall/  Upto  pelvic wall 
f) Rectal mucosa 
g) Proctoscopy- 
 
1. Blood tests Hb    TC    DC      Platelets Creatinine    LFT 
 
2. USG  Normal (1)/ Abnormal (2) 
 
3. Cxr  Normal (1)/ Abnormal (2) 
 
 
APPENDIX   II 
INFORMED CONSENT FORM 
A  pilot  project  to  study  the  feasibility  of  interdigitating  HDR  brachytherapy  with  Concurrent 
Chemoirradiation in carcinoma cervix    I confirm that I have read and understood the information sheet 
dated  ‐‐‐‐‐‐‐‐‐‐‐‐for  the above  study and have had  the opportunity  to ask questions and  to  clarify any 
doubt that I have. 
               I understand that my participation  in the study  is voluntary and that  I am free to withdraw at 
anytime without giving any reason without any medical care or legal rights being affected. I also affirm 
that no claim for money or any other financial or legal redressal would be made by me as a result of my 
participation in this study. I understand that the researcher of the clinical trial, the ethics committee and 
the regulatory authorities will have my permission to  look at my health records both  in respect of the 
current study and any further research that may be conducted in relation to it even if I withdraw from 
the  trial.  I  agree  to  this  access. However  I  understand  that my  identity will  not  be  revealed  in  any 
information released to the third parties or published. 
               I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose. I am fully aware of the procedures, its advantages and the possibility of  
radiation injury that I maybe susceptible. I have been informed about the purpose of the clinical study. 
                I voluntarily agree to take part in the above study and I understand that I could withdraw from 
the trial at any  time frame. 
       
 
Signature of Patient 
/ Her Thumb 
Impression  
Name of Patient  Date of 
Signature 
Time 
       
 
Signature of LAR   Name of LAR  Date of 
Signature 
Time 
       
Signature of Doctor 
obtaining  Consent 
Name of Doctor  Date of 
Signature 
Time 
 
Information to the patient 
It  is  for  the  information  that you have been diagnosed  to have Cancer of  the cervix stage  ‐‐‐‐‐  (FIGO).  
The  current  recommended  therapy  is  concurrent  chemoradiation with weekly  administered Cisplatin 
followed by brachytherapy. 
We are  inviting you  to participate  in  the  study  conducted  in  the Dept. of Radiation Oncology Unit  II, 
Christian Medical College, Vellore in patients with carcinoma of the cervix.  It is planned that this study 
will  involve  interdigitation  of  HDR  brachytherapy  with  external  radiotherapy  along  with  concurrent 
chemotherapy with Cisplatin.   
 
Many trials have been done in the western world and was found that interdigitating brachytherapy with 
external radiation  leads to reduction  in the overall treatment time and  later translates  into good  local 
control. We try to assess the feasibility of usage of this treatment protocol in routine clinical practice if 
the side effects are tolerable by the Indian  patients and if the response rate achieved is better than the 
standard practice. 
 
In this study your treatment will be the same as the recommended practice with the only difference of 
starting brachytherapy before external beam radiation therapy is completed.  You are free to withdraw 
from this study at any point of time.  We assure that withdrawal from the study will not affect the rest of 
your treatment in any way and it will be continued as per the recommended treatment. 
 
Risks associated with Radiation Therapy to the Pelvis 
Very Likely 
• Low blood counts causing easy bruising 
• Shortening and narrowing of the vagina 
• Pain with sexual intercourse 
• Tiredness near the end of treatment 
• Diarrhea , Nausea and/or vomiting 
• Stomach pain that feels like bad heartburn or an ulcer and that may make eating or 
drinking difficult; if you become dehydrated, you may need toreceive fluids through your 
vein 
• Poor digestion of food 
• Weight loss; if this is severe, you may need a tube placed into your stomach to provide 
nutrition 
• Rectal irritation 
• Urinary frequency and difficulty 
• Loss of pubic hair 
• Reddening and irritation of the skin in the treatment area 
Less Likely But Serious 
• Rectal ulcer 
• Bleeding or narrowing of the rectum 
• Bloody urine 
• Pain, bleeding, and/or blockage of the stomach or other parts of the digestive system 
• Ureteral (tube connecting kidneys to the bladder) obstruction 
• Fistula (opening) forming between pelvic tissues 
Reproductive risks 
This study may be harmful to an unborn child. Therefore, participants who are still menstruating 
and have not been surgically sterilized must have a negative pregnancy 
test prior to participating in this study. The results will be made available to you 
prior to the initiation of this study. Ask about counseling and more information 
about preventing pregnancy. You should not nurse your baby while on this study. 
 
Radiation to the pelvis will cause sterility, and you will not be able to become 
pregnant after treatment. Young women will go through menopause, and 
medication will be given to help with the symptoms of menopause. 
 
Risks Associated with Cisplatin 
 
Very Likely 
 
Decrease in blood counts which can lead to a risk of infection and bleeding. 
Loss of appetite and/or taste; metallic taste in your mouth 
Nausea and/or vomiting 
Fatigue 
Hearing loss or ringing in the ears 
Numbness or tingling in the hands or feet 
 
Less Likely 
 
Muscle cramps or spasm 
Loss of coordination 
Involuntary movements or shaking 
Loss of muscle or nerve function which may cause weakness or numbness in your hands and feet 
Facial swelling 
 
Less Likely, But Serious 
 
A decrease in the kidneys’ ability to handle the body’s waste, which may be permanent. 
Allergic reactions which can cause difficulty breathing, fast heartbeat, and sweating 
Decrease in liver function 
Another cancer called Acute Leukemia 
 
 
PERSONS TO CONTACT FOR FURTHER INFORMATION AND IN IMMEDIATE NEED: 
Dr Subhashini John, Department of Radiation Oncology, Christian Medical College, Vellore 
Dr Rajesh I, Department of Radiation Oncology, Christian Medical College, Vellore 
Dr Rajesh B, Department of Radiation Oncology, Christian Medical College, Vellore 
Dr Patricia S, Department of Radiation Oncology, Christian Medical College, Vellore 
 
Taking part in this study is completely your choice.  If you decide to participate, you will be asked to sign 
the consent form.  Kindly sign the consent form only when you understand the information given in the 
form and have had your questions answered to your complete satisfaction and understanding.  You will 
be given a copy of the signed form which you should keep for your personal records. 
Any questions about the study or clarification can be cleared with Dr. David Mathew or with the co‐
investigators of this trial. 
COSTS:  There is no extra cost to be paid for this study. Patients have to pay for the radiation therapy, 
Brachytherapy  and concurrent  chemotherapy as per the current practice. 
PAYMENT:  You will not be paid for participating in this trial. 
PARTICIPANT’S STATEMENT:   
I have read the consent form and the information sheet and have discussed with Dr_______________ 
about the study method and procedures.  I have been given the opportunity to ask questions which 
have been answered to my satisfaction.  I understand that my participation in this study is voluntary and 
that I may refuse to participate.  I also understand that if, for any reason, I wish to withdraw my 
participation, I will be free to do so and that this will have no effect on my further treatment. 
I hereby declare that I have been fully informed about the study with its risks and benefits and consent 
to participate in this trial with my full consciousness. 
       
Signature of Patient / Her 
Thumb Impression  
Name of Patient  Date of Signature  Time 
       
Signature of LAR   Name of LAR  Date of Signature  Time 
       
Signature of Doctor obtaining  
Consent 
Name of Doctor  Date of Signature  Time 
 
